(MENAFN- Arab Times) The Ministry of Health recently approved the registration of Daclatasvir € a new medication for Hepatitis C, reports Al-Qabas daily quoting sources. Sources confirmed the medicine has been found to be 100 percent effective and it is used in a therapeutic program which is implemented within a short period. Sources explained this medicine is being used along with Sofosbuvir as an advanced treatment and this has been proven successful through clinical experiments with patients including those suffering from advanced stages of the liver disease and failed to use other drugs. Results showed that taking this drug orally once a day has an impact on Hepatitis C genotype 3 which is considered the most treatment-resistant and most aggressive, sources added.
Meanwhile, Qatari Director of the Gulf Bristol-Myers Squibb Jimitris Carolus asserted Hepatitis has been a source of anxiety in Kuwait, particularly the Ministry of Health, due to the nature of the disease. He said they will support the Kuwaiti government in its fight against Hepatitis C through Daclatasvir. On the other hand, Dean of the Faculty of Medicine at Kuwait University Dr Fouad Al-Ali stressed the ministry's decision to approve the registration of Daclatasvir will be beneficial to a large number of patients suffering from different genotypes of Hepatitis C, especially genotype 3. He added Kuwait is considered one of the first among the GCC countries to join the Global Alliance against Hepatitis which aims to support more than 400 million people suffering from hepatitis around the world.
Meanwhile, the Ministry of Health has obtained approval from all supervising authorities to provide hospitals with injections for the treatment of fungal infections with a total cost of KD1.178 million, reports Al-Qabas daily quoting sources. Sources said the ministry also got approval for the supply diabetes medicines to medical centers and hospitals with a total cost of KD800,000; medicines to control cholesterol worth KD737,000; medicines for high blood pressure worth KD599,000; x-rays and radiation therapy devices and their accessories for Jahra and Sabah hospitals with a total cost of KD932,000; devices and their accessories for the Nuclear Medicine Department at Kuwait Cancer Control Center at a cost of KD50,000; injections for cancer patients in Hussein Makki Al-Jum'a Center at a cost of KD199,000; and injections for patients suffering from endocrine diseases at a cost of KD192,000. Sources also unveiled a plan to construct a new building for Casualties Department in Adan Hospital, disclosing the project will be launch soon in order to obtain approval from the official bodies.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.